Prelude Capital Management’s NxStage Medical Inc. NXTM Stock Holding History

Prelude Capital Management’s Portfolio NXTM Stock Details NXTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-78,032	Closed	-$2.23M	–	2394
2018 Q4	$2.23M	Buy	78,032 +36,012	+86%	+$1.02M	0.15%	148
2018 Q3	$1.17M	Buy	42,020 +19,020	+83%	+$535K	0.07%	337
2018 Q2	$642K	Sell	23,000 -10,842	-32%	-$291K	0.04%	456
2018 Q1	$841K	Buy	33,842 +21,966	+185%	+$534K	0.06%	317
2017 Q4	$288K	Buy	11,876 +7,376	+164%	+$194K	0.02%	535
2017 Q3	$124K	Buy	+4,500	New	+$120K	0.01%	818
2016 Q1	–	Sell	-1,343	Closed	-$29K	–	1673
2015 Q4	$29K	Buy	+1,343	New	+$25K	﹤0.01%	1153
2015 Q3	–	Sell	-1,150	Closed	-$16K	–	1941
2015 Q2	$16K	Buy	+1,150	New	+$19.5K	﹤0.01%	1494

Other funds holding NXTM

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Prelude Capital Management's NXTM Position: Q1 2019 in Review

Prelude Capital Management sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 78,032 shares — an estimated $2.23M sold.

Prelude Capital Management first reported a position in NXTM in Q2 2015 and held it in 8 quarters. The position peaked at $2.23M in Q4 2018. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.

Prelude Capital Management reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
Prelude Capital Management sold 78,032 NxStage Medical Inc. shares in Q1 2019, an estimated $2.23M.
Prelude Capital Management first reported a position in NxStage Medical Inc. in Q2 2015 and held it in 8 quarters.
Prelude Capital Management's NxStage Medical Inc. position peaked at $2.23M in Q4 2018.
1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.